Fate Therapeutics

FATE · Nasdaq · United States

Share price · FATE

$1.05-1.51 (-58.98%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.9M (1.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when FATE's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 17 Nov 2026-10.5%
  2. 16 Nov 2026-10.9%
  3. 12 Nov 2026-16.5%
  4. 11 Nov 2026-9.3%
  5. 10 Nov 2026-8.8%
  6. 20 Oct 2026+10.8%
  7. 3 Jun 2026-13.6%
  8. 5 May 2026+31.1%
  9. 4 May 2026+17.6%
  10. 1 May 2026+22.4%

Share of unusual movement by asset

For each asset, the share of FATE's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

Assets

(4 total)
4Total Assets
0Approved
0Phase 3 / Filed
4Phase 1–2 / Early
3Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Phase 2
CD19Cell therapy
Systemic Lupus Erythematosus
Phase 1
BCMACell therapy
Multiple Myeloma
Phase 1
MICA/MICB (alpha-3 domain)Cell therapy
Non-Small Cell Lung Cancer
Preclinical / Unstaged
CD19Cell therapy
Systemic Lupus Erythematosus

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
July 2029 (1)
FT819Phase 2Lupus Nephritis, Systemic Lupus Erythematosus, SLE - Systemic Lupus Erythematosus, Lupus Nephritis - WHO Class III …
Est. primary completion 2029-07-01 · NCT07570862 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0$24M$44M+ $95M short-term inv.$31M-$28M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$2.1M$24M$32M+ $121M short-term inv.$30M-$23M operating cash flowreport ↗
2026-Q1$1.3M$25M$40M+ $135M short-term inv.$31M-$31M operating cash flowreport ↗
2025-Q3$1.7M$26M$41M+ $175M short-term inv.$32M-$24M operating cash flowreport ↗
2025-Q2$1.9M$27M$41M+ $182M short-term inv.$34M-$25M operating cash flowreport ↗
2025-Q1$1.6M$29M$45M+ $196M short-term inv.$38M-$34M operating cash flowreport ↗
2024-Q3$3.1M$35M$38M+ $259M short-term inv.$48M-$29M operating cash flowreport ↗
2024-Q2$6.8M$35M$37M+ $268M short-term inv.$38M-$32M operating cash flowreport ↗
2024-Q1$1.9M$32M$121M$48M-$33M operating cash flowreport ↗
2023-Q3$1.9M$34M$33M$45M-$38M operating cash flowreport ↗
2023-Q2$0.9M$41M$47M$53M-$28M operating cash flowreport ↗
2023-Q1$59M$66M$42M$19M-$29M operating cash flowreport ↗
2022-Q3$15M$80M$82M$84M-$55M operating cash flowreport ↗
2022-Q2$19M$81M$55M$76M-$53M operating cash flowreport ↗
2022-Q1$18M$72M$65M$66M-$65M operating cash flowreport ↗
2021-Q3$14M$53M$129M$43M-$33M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$6.7M$108M$47M+ $157M short-term inv.$34M-$106M operating cash flowreport ↗

For the full year 2025, Fate Therapeutics reported revenue of $6.65M, down 51.2% YoY from $13.63M, and R&D spend of $107.83M, down 20.1% YoY from $135M. Cash and equivalents were $46.63M, with a net loss of $136.31M and quarterly net burn of $136.32M.

Management projected operating runway through year-end 2027, supported by $205.1M in cash, cash equivalents, and investments and a 30% reduction in 2025 operating expenses versus 2024. Clinically, FT819 advanced as an outpatient, same-day-discharge off-the-shelf CAR T-cell therapy in an autoimmune basket study, with 15 systemic lupus erythematosus patients, four systemic sclerosis patients, and one idiopathic inflammatory myopathy patient treated, and the first systemic sclerosis patient showed meaningful disease improvement at the three-month evaluation. FT836, a MICA/B-targeted off-the-shelf CAR T-cell therapy, demonstrated early colorectal cancer activity, including a greater than 50% reduction in CEA levels and tumor reduction across all target lesions without conditioning chemotherapy. FT839 preclinical data were also presented, with IND-enabling activities ongoing.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$14M$135M$36M+ $243M short-term inv.$47M-$123M operating cash flowreport ↗
2023-FY$64M$173M$42M+ $273M short-term inv.$40M-$132M operating cash flowreport ↗
2022-FY$96M$320M$61M+ $375M short-term inv.$70M-$248M operating cash flowreport ↗
2021-FY$56M$216M$134M+ $482M short-term inv.$53M-$163M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 7 sales ($336K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-03Adawi Kamal · Chief Financial OfficerOpen-market sale6,582$2.05$14KForm 4
2026-08-04Valamehr Bahram · director, President and CEOOpen-market sale43,947$2.46$108KForm 4
2026-08-04TAHL CINDY · See RemarksOpen-market sale38,800$2.46$95KForm 4
2026-06-12Hamill Laura · directorAward / grant (derivative)175,800——Form 4
2026-06-12RASTETTER WILLIAM H · directorAward / grant (derivative)87,900——Form 4
2026-06-12ABERNETHY MATT · directorAward / grant (derivative)87,900——Form 4
2026-06-12Agarwal Shefali · directorAward / grant (derivative)87,900——Form 4
2026-06-12EPSTEIN ROBERT S · directorAward / grant (derivative)87,900——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 155 reporting institutions held 74.1M shares ($83.2M, 63.6% of shares outstanding).

#InstitutionSharesValue
1Redmile Group, LLC12,872,946$15.4M
2BlackRock, Inc.10,068,614$12.1M
3VANGUARD CAPITAL MANAGEMENT LLC4,192,063$5.0M
4VANGUARD PORTFOLIO MANAGEMENT LLC4,134,585$5.0M
5TWO SIGMA INVESTMENTS, LP3,466,786$4.2M
6JOHNSON & JOHNSON3,379,064$4.1M
7AQR CAPITAL MANAGEMENT LLC3,001,521$3.6M
8RENAISSANCE TECHNOLOGIES LLC2,974,683$3.6M
9GEODE CAPITAL MANAGEMENT, LLC2,590,429$3.1M
10STATE STREET CORP2,263,173$2.7M
11UBS Group AG1,821,715$2.2M
12GOLDMAN SACHS GROUP INC1,327,757$1.6M
13TANG CAPITAL MANAGEMENT LLC1,167,773$1.4M
14CITADEL ADVISORS LLC942,926$1.1M
15DIMENSIONAL FUND ADVISORS LP883,790$1.1M